healio.com /2 weeks ago

Zanidatamab regimens improve survival for gastroesophageal cancer

First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...

Read source
emcrit.org /1 month ago

A Study in Priors Part 3

In 2010, the CRASH-2 trial was published in the Lancet.[1] The authors randomized 20,211 trauma patients with, or at risk of, significant hemorrhage within 8 hours of injury to eit...

Read source
biopharmadive.com /5 days ago

CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial

CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares. 

Read source
cleveland.com /2 weeks ago

Major heart drug trial falls short of expectations

A Cleveland Clinic-led trial found that pelacarsen reduced Lp(a) levels by 78.4% but failed to lower rates of major cardiovascular events compared to a placebo over nearly five yea...

Read source
qchron.com /3 weeks ago

Results of CARsgen's Satri-cel for Adjuvant Treatment for Gastric Cancer Presented at ESMO Congress 2026

SHANGHAI, Oct. 25, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Related searches